Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
48-month open-label extension study of E2007 in Parkinson's disease with wearing-off motor fluctuations and on-period dyskinesias
2004-000361-35Phase 2Terminated
- Sponsor
- Eisai Co., Ltd.
- Start
- Oct 2004
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of perampanel in Parkinson's disease (PD), sponsored by Eisai Co., Ltd. Primary endpoint: Long-term safety and tolerability of E2007. Started Oct 2004; status: terminated.
02
Drugs
perampanel
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2004-000361-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000361-35.